title: A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer.
abstract: BACKGROUND
  At present the addition of thoracic irradiation to combination chemotherapy is a standard treatment for limited staged small cell lung cancer. However, there is still controversy about the optimum timing of chest irradiation. We conducted a phase II study of etoposide (VP-16)-ifosfamide-cisplatin (VIP) combination chemotherapy plus early concurrent thoracic irradiation for the patients with previously untreated limited small cell lung cancer in order to assess if the treatment modality could improve the response rate and the toxicity.
  
  
  METHODS
  Forty-four patients with limited small cell lung cancer were treated with etoposide-ifosfamide-cisplatin and concurrent thoracic irradiation. Combination chemotherapy consisted of etoposide 100 mg/m2 (on days 1-3), ifosfamide 1000 mg/m2 (on days 1 and 2) and cisplatin 100 mg/m2 (on day 1). Concurrent thoracic irradiation consisted of a total of 4000 cGy over 4 weeks starting on the first day of the first chemotherapy. All patients who showed a complete response were given prophylactic cranial irradiation for 2.5 weeks.
  
  
  RESULTS
  Forty-four of the 49 patients who entered the study from May 1994 to August 1998 were evaluable. The median age was 59 years and 40 patients had a performance status of 0 or 1. The median survival time was 22.5 months. Twenty-eight patients (62%) showed a complete response and 16 (38%) a partial response. Twenty-four patients (54%) developed grade 3 or 4 neutropenia; there was a 9% RTOG score 3 or 4 esophagitis.
  
  
  CONCLUSIONS
  VIP combination chemotherapy and early concurrent thoracic irradiation for patients with limited stage small cell lung cancer revealed excellent antitumor response with tolerable toxicity.
authors.affiliation: Department of lnternal Medicine, College of Medicine, Hallym University, Seoul, Korea.
authors.forename: I S
authors.initials: IS
authors.lastname: Woo
authors.forename: Y S
authors.initials: YS
authors.lastname: Park
authors.forename: S H
authors.initials: SH
authors.lastname: Kwon
authors.forename: Y L
authors.initials: YL
authors.lastname: Park
authors.forename: J A
authors.initials: JA
authors.lastname: Lee
authors.forename: M J
authors.initials: MJ
authors.lastname: Park
authors.forename: I G
authors.initials: IG
authors.lastname: Hyun
authors.forename: K S
authors.initials: KS
authors.lastname: Jung
authors.forename: H S
authors.initials: HS
authors.lastname: Bae
authors.forename: D H
authors.initials: DH
authors.lastname: Oh
authors.forename: W S
authors.initials: WS
authors.lastname: Kim
authors.forename: K
authors.initials: K
authors.lastname: Park
authors.forename: C H
authors.initials: CH
authors.lastname: Park
authors.forename: H J
authors.initials: HJ
authors.lastname: Kim
authors.forename: Y C
authors.initials: YC
authors.lastname: Ahn
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D013909:Thorax / Q000528:radiation effects*
chemical_list: D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide